A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Integrated Clinical Trial Services, Inc., West Des Moines, Iowa
Conditions: Obesity
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Obesity, Cardiovascular Diseases
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/17/2025
Locations: Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)